Although more studies are needed to fully identify the role of the Nrf2 and MAPKs/NF-κB pathways, it is reasonable to suggest that pharmacological modulation of these pathways may provide a new therapeutic target in HD. The gene discussed is NFE2L2; the disease is Huntington disease.